Biotechnology

With key advisory appointments, NeuraClick aims to overcome long-standing hurdles in peptide drug development for complex brain and metabolic disorders.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

A CEO's personal battle with prostate cancer inspired a community golf tournament that is now on the verge of raising $1 million for critical research.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

At a major oncology conference, Zephyr AI will showcase AI that predicts patient response to targeted therapies, aiming to personalize cancer treatment.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

Following a major partnership, AST and Marchesini Group will showcase next-gen robotic filling and inspection tech, aiming to reshape sterile drug production.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.

OncoHost's new research shows a patient's "biological age" can predict immunotherapy success, a potential breakthrough in personalized oncology.

With a fresh $28M investment, Verismo Therapeutics is set to unveil groundbreaking KIR-CAR data, aiming to revolutionize CAR T therapy for solid tumors.

Atelerix's revolutionary hydrogel eliminates the need for cold chain logistics, partnering with JH Health to unlock the booming Saudi biotech market.

Shanghai's SinoUnited Health is attracting global patients with advanced care like CAR-T therapy at a fraction of US prices, challenging medical tourism hubs.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Win a VIP trip to meet P!NK while supporting vital cancer research. A new fundraising model emerges as public funding for life-saving science dwindles.

Phase 3 data shows GTx-104 reduces key risks and improves outcomes for aSAH patients, positioning it as a potential new standard of care ahead of an FDA decision.

MeiraGTx will present 3-year data on a one-time therapy for radiation-induced dry mouth, a condition affecting millions of head and neck cancer survivors.

Biotech firm Genvor leverages its AI platform in a new partnership, aiming to fast-track novel peptides for anti-aging and weight loss to a booming market.